<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Damien</forename><surname>Bonnet</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Hôpital Necker Enfants Malades</orgName>
								<address>
									<postCode>M3C</postCode>
									<settlement>Necker</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">AP-HP</orgName>
								<orgName type="institution" key="instit2">Université Paris Descartes</orgName>
								<orgName type="institution" key="instit3">Sorbonne Paris Cité</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Felix</forename><surname>Berger</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Congenital Heart Disease and Pediatric Cardiology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Deutsches Herzzentrum Berlin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Eero</forename><surname>Jokinen</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Division of Pediatric C</orgName>
								<orgName type="institution">Helsinki University Children&apos;s Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Paul</forename><forename type="middle">F</forename><surname>Kantor</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">University of Alberta</orgName>
								<orgName type="institution" key="instit2">Stollery Children&apos;s Hospital</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>DM</roleName><forename type="first">Piers</forename><forename type="middle">E F</forename><surname>Daubeney</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Royal Brompton Hospital and Imperial College</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Edwards, Gore Medical, Medtronic, Novartis</roleName><forename type="first">Pfizer</forename><surname>Actelion</surname></persName>
						</author>
						<author>
							<persName><roleName>Philips, Servier</roleName><forename type="first">St</forename><surname>Pharma</surname></persName>
						</author>
						<author>
							<persName><roleName>Dr</roleName><surname>Jude</surname></persName>
						</author>
						<title level="a" type="main">Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B36F129E5E23988555B903AF690E6BEC</idno>
					<idno type="DOI">10.1016/j.jacc.2017.07.725</idno>
					<note type="submission">received May 18, 2016; revised manuscript received July 5, 2017, accepted July 10, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:10+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>heart rate</term>
					<term>left ventricular ejection fraction</term>
					<term>N-terminal pro-B-type natriuretic peptide</term>
					<term>pediatric</term>
					<term>quality of life</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>BACKGROUND Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF).</s></p><p><s>Ivabradine has shown promising efficacy, but has not been evaluated in children.</s><s>Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults.</s></p><p><s>OBJECTIVES The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF.</s><s>The primary endpoint was $20% reduction in heart rate from baseline without inducing bradycardia or symptoms.</s></p><p><s>METHODS This was a randomized, double-blind, placebo-controlled, phase II/III study with 12 months of follow-up.</s></p><p><s>Children (n ¼ 116) receiving stable HF therapy were randomized to either ivabradine or placebo.</s><s>After an initial titration period, the dose was adjusted to attain the primary endpoint.</s><s>Left ventricular function (echocardiography), clinical status (New York Heart Association functional class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) were assessed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>The primary endpoint was reached by 51 of 73 children taking ivabradine (70%) versus 5 of 41 taking placebo (12%) at varying doses (odds ratio: 17.24; p &lt; 0.0001).</s><s>Between baseline and 12 months, there was a greater increase in left ventricular ejection fraction in patients taking ivabradine than placebo (13.5% vs. 6.9%;</s><s>p ¼ 0.024).</s><s>New York Heart Association functional class or Ross class improved more with ivabradine at 12 months than placebo (38% vs. 25%; p ¼ 0.24).</s><s>There was a trend toward improvement in QOL for ivabradine versus placebo (p ¼ 0.053).</s><s>N-terminal pro-B-type natriuretic peptide levels decreased similarly in both groups.</s><s>Adverse events were reported at similar frequencies for ivabradine and placebo.</s></p><p><s>CONCLUSIONS Ivabradine safely reduced the resting heart rate of children with chronic HF and dilated cardiomyopathy.</s><s>Ivabradine's effect on heart rate was variable, highlighting the importance of dose titration.</s><s>Ivabradine treatment improved left ventricular ejection fraction, and clinical status and QOL showed favorable trends.</s></p><p><s>(Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure from ages 6 months to 18 years; ISRCTN60567801)</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>A n important cause of mortality and morbidity in children, pediatric heart failure (HF) contributes substantially to health care costs <ref type="bibr" target="#b0">(1)</ref>.</s><s>Pediatric cardiomyopathies are a prominent cause of HF in children, with an annual incidence of 11 to 12 children per million/year in the United States and Australia <ref type="bibr" target="#b1">(2,</ref><ref type="bibr" target="#b2">3)</ref>.</s><s>Dilated cardiomyopathy (DCM) represents one-half of all cardiomyopathies in children.</s></p><p><s>Although the overall incidence of pediatric DCM is low, it is higher in children age &lt;1 year (44 cases per million/year) than in children older than age 3 years (3.4 cases per million/year) <ref type="bibr" target="#b3">(4)</ref>.</s><s>Although some children recover normal left ventricular (LV) function and size <ref type="bibr" target="#b4">(5)</ref>, DCM is often associated with poor outcomes.</s><s>Approximately 40% of children undergo cardiac transplantation or die within 5 years of DCM diagnosis, attesting to the importance of HF in this patient population <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b7">7)</ref>.</s></p><p><s>Management of children with chronic HF can be challenging.</s><s>Proposed treatment guidelines for HF in childhood have been hampered by a paucity of evidence-based pediatric data <ref type="bibr" target="#b8">(8,</ref><ref type="bibr" target="#b9">9)</ref>.</s><s>Available therapies include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretic agents, and digoxin <ref type="bibr" target="#b11">(10,</ref><ref type="bibr" target="#b12">11)</ref>.</s><s>However, with a lack of clinical trials, these treatments are not approved for use in children.</s></p><p><s>Nonetheless, these agents have been shown to be beneficial in small studies as well as in current practice, and as such, they are proposed in the guidelines for the management of chronic HF in children <ref type="bibr" target="#b8">(8,</ref><ref type="bibr" target="#b9">9)</ref>.</s></p><p><s>To date, no randomized controlled trial of any medication has demonstrated a significant improvement of HF outcomes in pediatric patients.</s><s>A study in 161 children ages 0 to 17 years with chronic HF <ref type="bibr" target="#b13">(12)</ref> indicated that the beta-blocker carvedilol had no significant effect on chronic HF outcomes in children compared with placebo, although there was some improvement in left ventricular ejection fraction (LVEF).</s></p><p><s>In adults, an elevated heart rate is associated with an increased risk of death in patients with chronic HF <ref type="bibr" target="#b14">(13)</ref><ref type="bibr" target="#b15">(14)</ref><ref type="bibr" target="#b16">(15)</ref>.</s><s>Ivabradine, an effective heart rate-reducing agent, lowers incidence of cardiovascular death and hospitalization for worsening HF in adult patients, with a relative risk reduction of 18% in a trial setting (p &lt; 0.0001) <ref type="bibr" target="#b17">(16)</ref>.</s><s>Ivabradine is recommended for the treatment of chronic HF in adults with an elevated heart rate and in sinus rhythm <ref type="bibr" target="#b18">(17)</ref>.</s><s>There are no corresponding data for ivabradine in children.</s><s>The objective of our study was to document the effect of ivabradine therapy in a pediatric population age 6 months to 18 years with DCM and symptomatic chronic HF.</s><s>We explored the dose of ivabradine that was necessary to reach a $20% reduction in heart rate, and we evaluated its tolerance.</s><s>We also describe its effect on clinical symptoms, LV function, quality of life (QOL), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) values.</s><s>(documented by echocardiography) on stable treatment for chronic HF were considered eligible.</s><s>Patients enrolled were stratified into 3 subgroups (age 6 to 12 months, &gt;1 year and &lt; 3 years, and 3 to 18 years), and were then randomly allocated to treatment with either ivabradine or placebo in a 2:1 ratio.</s><s>Treatment was allocated via a centralized interactive randomization response system.</s><s>The primary objectives of the study were to: 1) determine the optimal dose of ivabradine to reach a target heart rate reduction of $20% without bradycardia; and 2) assess the pharmacokinetic profile and pharmacokineticpharmacodynamic relationship of ivabradine in children.</s><s>This report describes the results pertaining to the target heart rate reduction.</s><s>Pharmacokinetic results have been reported in separate publications <ref type="bibr" target="#b20">(19,</ref><ref type="bibr" target="#b22">20)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p><s>Study inclusion required HF functional class to be stable for at least 4 weeks prior to selection.</s><s>Eligible patients were in sinus rhythm with resting heart rates in the normal range for age: $105 beats/min for patients ages 6 to 12 months, $95 beats/min for &gt;1 year and &lt;3 years, $75 beats/min for 3 to 5 years, and $70 beats/min for 5 to 18 years; these values were predefined according to normal limits reported in healthy pediatric patients <ref type="bibr" target="#b23">(21)</ref>.</s><s>Lower-limit values were pre-specified, because most patients were already receiving beta-blockers.</s><s>The minimal resting heart rate at inclusion for 5-to 18-year-olds was fixed at $70 beats/min based on studies in adults <ref type="bibr" target="#b17">(16)</ref>.</s><s>Neonates and infants (age &lt;6 months) were excluded due to concerns over tolerability of the use of 2 heart ratelowering agents (beta-blockers and ivabradine) <ref type="bibr" target="#b24">(22,</ref><ref type="bibr">23)</ref>.</s><s>PROCEDURES AND ENDPOINTS.</s><s>There was a 2-to 8-week titration period with periodic visits.</s><s>Previous results in adults showed that the greatest heart rate reduction with ivabradine (19% to 25%) was obtained in patients with the highest heart rate at baseline, which correlated with the greatest improvement in outcome events versus placebo <ref type="bibr" target="#b25">(24)</ref>.</s><s>A mean heart rate reduction of 20% was observed to be clinically beneficial for adult patients in the SHIFT (Ivabradine and Outcomes in Chronic Heart Failure) study <ref type="bibr" target="#b17">(16)</ref>.</s><s>Consequently, the dosage of study treatment was uptitrated to achieve a $20% reduction in heart rate without inducing bradycardia or its symptoms.</s><s>Bradycardia was defined as a heart rate of &lt;80 beats/min for patients ages 6 to 12 months, &lt;70 beats/min for &gt;1 year and &lt;3 years, and &lt;50 beats/min for 3 to 18 years.</s><s>If the patient experienced bradycardia, the study drug was downtitrated to the next lowest dosage.</s></p><p><s>Study treatment was administered as an oral liquid at a starting dose of 0.02 mg/kg twice daily for children ages 6 to 12 months and 0.05 mg/kg twice daily for children ages &gt;1 year and &lt; 3 years or 3 to 18 years.</s><s>This liquid ivabradine was specially formulated for this pediatric study, and was delivered as single-dose units of 10 ml containing 1, 5, or 13.3 mg of ivabradine (stored at room temperature).</s><s>The tablet form (adult formulation) was administered to children weighing $40 kg with a starting dose of 2.5 mg twice daily.</s><s>The doses could be adjusted every 2 weeks (increased, decreased, or maintained).</s><s>The duration of the titration period was governed by the magnitude of heart rate reduction and could last up to 8 weeks or until the patient reached the primary endpoint ($20% reduction in heart rate without bradycardia or symptoms of bradycardia).</s><s>Titration could involve a maximum of 4 steps.</s><s>Patients who were initiated on 0.02 mg/kg twice daily could be uptitrated to 0.05, 0.10, 0.15, and 0.20 mg/kg twice daily, and those initiated on 0.05 mg/kg twice daily could be uptitrated to 0.10, 0.15, 0.20, and 0.30 mg/kg twice daily.</s><s>Patients weighing $40 kg, who started on 2.5 mg twice daily (tablet form), could be uptitrated to 5, 7.5, 10, and 15 mg twice daily.</s></p><p><s>The titration period was followed by a 2-week maintenance period.</s><s>This was followed by monitoring for a further 12 months on treatment, with monthly visits up to 3 months, and then visits at 6, 9, and 12 months.</s></p><p><s>At every visit, patient heart rate was measured using any method, provided that the child was quiet and at rest, and the dose of study treatment was recorded.</s></p><p><s>The The baseline characteristics are presented as means AE SD for continuous variables and as numbers    A similar and substantial decrease in NT-proBNP was observed in both the ivabradine and placebo groups between baseline and 12 months.</s><s>The decreases were À710 AE 1,478 pg/ml (median À128 pg/ml) with ivabradine and À367 AE 576 pg/ml (median À129 pg/ml) with placebo.</s><s>This randomized, double-blind, placebo-controlled trial explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure (HF).</s><s>The primary endpoint (reduction of $20% of heart rate from baseline without bradycardia) was reached in a significantly higher proportion in the treatment arm.</s><s>As to secondary endpoints, significant improvement of left ventricular ejection fraction (LVEF) was significantly better in the treatment arm; the other secondary endpoints were not significantly different but trended towards improvement with ivabradine.</s></p><p><s>heart rate at follow-up when treating chronic HF in children with DCM who are taking ivabradine.</s><s>The rates of known AEs with ivabradine, such as phosphenes and bradycardia, were in line with the rates observed in adults <ref type="bibr" target="#b17">(16)</ref>.</s><s>QTc prolongations were less frequent with ivabradine than placebo.</s><s>The results of the pharmacokinetic and pharmacodynamic analysis showed that the relationship described in adults was conserved in the pediatric population <ref type="bibr" target="#b20">(19,</ref><ref type="bibr" target="#b22">20)</ref>.</s></p><p><s>The majority of patients in this study were treated with combinations of recommended drugs (ACE inhibitors [94%], beta-blockers [76%], aldosterone antagonists [79%], and digitalis [50%]) <ref type="bibr" target="#b8">(8,</ref><ref type="bibr" target="#b31">30,</ref><ref type="bibr" target="#b32">31)</ref>, and had stable chronic HF with a long history of DCM.</s><s>As such, worsening events were infrequent, as shown by the limited number of heart transplantation and/or deaths in both groups.</s><s>Although improvement and normalization might occur in 20% of these patients <ref type="bibr" target="#b4">(5)</ref>, this is mainly observed by 24 months after diagnosis of DCM.</s><s>For these reasons, we consider that the observed trends in clinical status and QOL, although not statistically significant, might be clinically important.</s><s>Our results suggested that using ivabradine as an add-on therapy to standard of care therapy in children with chronic HF due to DCM might be beneficial and deserves further investigation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>STUDY DESIGN AND PATIENTS.</s><s>This was a randomized, double-blind, placebo-controlled, phase II/III study in 47 centers across 16 countries.</s><s>Children diagnosed with DCM with a history of class II to IV symptomatic HF (New York Heart Association [NYHA] functional class or Ross classification [18]), and an LVEF #45%</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>7 2</head><label>72</label><figDesc><div><p><s>The protocol was approved by the ethics committee or institutional review board at each center and conformed to the principles outlined in the Declaration of Helsinki.</s><s>The parents or guardians of allSEE PAGE 1273 A B B R E V I A T I O N S A N D A C R O N Y M S ACE = angiotensin-converting enzyme DCM = dilated cardiomyopathy HF = heart failure LV = left ventricle/ventricular LVEF = left ventricular ejection fraction LVESV = left ventricular end-systolic volume NT-proBNP = N-terminal pro-B-type natriuretic peptide QOL = quality of life J A C C V O L .</s><s>7 0 , N O . 1 0 , 2 0 1 Bonnet et al. S E P T E M B E R 5 , 2 0 1 7 : 1 2 6 2 -7 Ivabradine in Pediatric Heart Failure patients gave their written informed consent, and depending upon age and local regulations, children and adolescents also gave their informed assent.</s><s>The International Scientific Board had the overall scientific responsibility of the study, and the Data and Safety Monitoring Board operated independently of the study's sponsor and reviewed safety data.</s><s>The trial is registered on the European Clinical Trials Register (ISRCTN60567801).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>5 .</head><label>5</label><figDesc><div><p><s>mean dose was calculated in the per-protocol population by averaging the daily dose received during the titration period.</s><s>Electrocardiograms were reviewed centrally (CardiaBase, Nancy, France) for intervals and abnormalities.</s><s>Changes in LVEF (biplane Simpson method) and other echocardiographic parameters, clinical symptoms (NYHA functional class or Ross classification), and NT-proBNP were monitored as secondary endpoints.</s><s>Health-related QOL was evaluated in an optional substudy in a selection of countries and was assessed in children between 2 and 18 years of age using the Pediatric Quality of Life inventory (PedQL) 4.0 (25).</s><s>Parents of children ages 2 to 5 years responded to the questionnaire themselves.</s><s>Children ages 5 to 18 years personally responded to age-adapted questionnaires, as did their parents.</s><s>The improvement in total score (0 to 100 scale) was expressed as a change from baseline of &gt;4.The safety of ivabradine was monitored throughout the study.</s><s>Moreover, patients were hospitalized overnight for medical observation after the first treatment administration, and observed for at least 4 h after the second intake.</s><s>All treatmentemergent adverse events (AEs) were classified using the Medical Dictionary for Regulatory Activities (26).STATISTICAL METHODS.</s><s>The sample size was determined based on the pharmacokinetic objective, which was 1 of the study's primary objectives.</s><s>Considering the unbalanced design between ivabradine and placebo (2:1), it was estimated that at least 90 evaluable children were to be included in this study (60 ivabradine, 30 placebo) to explore the pharmacokineticpharmacodynamic relationship of ivabradine.</s><s>This number of patients allowed the detection of a difference of at least 10% in LVEF units between ivabradine and placebo, assuming an SD of 12%, with a 95% power and a type I error of 5% (2-sided), based on a Student t test.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 3 Functional</head><label>3</label><figDesc><div><p><s>FIGURE 3 Functional Class and LVEF</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>improvement in cardiac function, children tended to have better clinical status and QOL when treated with ivabradine compared with placebo.</s><s>Current recommendations for treatment of chronic HF in children are frequently extrapolated from adult clinical trials, and most of the widely used management strategies involve off-label prescription.</s><s>There are currently few pediatric formulations available in HF, and evidence-based data are scarce (5,12,27,28).</s><s>Our study was the first randomized, placebocontrolled trial of ivabradine in children with DCM and symptomatic chronic HF.</s><s>Our findings were broadly consistent with the beneficial effects of ivabradine demonstrated in adults, and with 2 anecdotal cases of adolescents with DCM in whom LVEF improved after treatment with ivabradine 7.5 mg twice daily (29).</s><s>In terms of safety, ivabradine was well-tolerated and safe for use in this study.</s><s>There were no serious bradycardic events.</s><s>However, the lack of bradycardic events might reflect the careful supervision of a structured titration period, supporting the notion that a titration period should be considered mandatory in children.</s><s>It remains important to monitor CENTRAL ILLUSTRATION Ivabradine in Children With Dilated Cardiomyopathy Bonnet, D. et al.</s><s>J Am Coll Cardiol.</s><s>2017;70(10):1262-72.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc><div><p><s>STUDY LIMITATIONS.</s><s>Attainment of the primary endpoint (heart rate reduction) alone did not prove that ivabradine is efficacious in treating children with DCM and HF.</s><s>This study was not powered to demonstrate a mortality advantage, and did not attempt to demonstrate a combined endpoint effect for treatment with ivabradine.</s><s>Data demonstrating efficacy on morbidity and mortality are more compelling, but require very large numbers of patients, which is unrealistic in pediatric HF.This study, as is frequently the case for pediatric HF, was limited by the number of patients available for recruitment, as pediatric DCM is an uncommon disease.</s><s>However, in comparison to other studies of this kind, our study population could be considered relatively robust, with an adequate length of followup.</s><s>Other limitations inherent in this patient population included the tendency to see an increase in LVEF over time, as was noted in the Pediatric Carvedilol Trial<ref type="bibr" target="#b33">(32)</ref>, and the difficulty in defining surrogate endpoints for a lack of improvement over time.Numerous surrogate endpoints used in adult studies of HF, such as hospitalization for HF, exercise capacity, QOL, LVEF, or NT-proBNP, have inherent difficulties in children, and are therefore not always useful to demonstrate the efficacy of add-on therapy combined with standard care.</s><s>Nonetheless, in this small study, we were encouraged to see significant improvement (LVEF) or trends in improvement (HF class, QOL) in most of these indicators, and we feel that an efficacy study of ivabradine in pediatric HF may well be warranted.CONCLUSIONSIvabradine has a good safety profile and was associated with a significant reduction in resting heart rate of children with chronic HF and DCM in all age subgroups tested from 6 months to 18 years.</s><s>Children treated with ivabradine also showed significant improvement in echocardiographic indexes (LVEF and LVESV) and a favorable trend for clinical status and QOL compared with placebo.</s><s>Importantly, this study provided more data on the efficacy and safety of treating children with DCM and chronic HF with ivabradine and highlighted the importance of a titration period.</s><s>Further pediatric studies such as this are required to enable physicians to make evidencebased decisions in the management of pediatric heart failure patients.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1</head><label>1</label><figDesc></figDesc><table><row><cell>Baseline Demographics</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Ivabradine</cell><cell>Placebo</cell><cell>All</cell></row><row><cell></cell><cell>(n ¼ 74)</cell><cell>(n ¼ 42)</cell><cell>(N ¼ 116)</cell></row><row><cell>Demographic characteristics</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age, yrs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>5.8 AE 5.1</cell><cell>5.8 AE 4.6</cell><cell>5.8 AE 4.9</cell></row><row><cell>Median (range)</cell><cell>3.4 (0.5-17.2)</cell><cell>5.3 (0.6-15.8)</cell><cell>3.9 (0.5-17.2)</cell></row><row><cell>6-12 months</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>0.7 AE 0.2</cell><cell>0.7 AE 0.1</cell><cell>0.7 AE 0.2</cell></row><row><cell>Median (range)</cell><cell>0.8 (0.5-1.0)</cell><cell>0.7 (0.6-1.0)</cell><cell>0.7 (0.5-1.0)</cell></row><row><cell>n</cell><cell>1 0</cell><cell>7</cell><cell>1 7</cell></row><row><cell>&gt;1 yr and &lt; 3 yrs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>2.2 AE 0.6</cell><cell>2.1 AE 0.6</cell><cell>2.1 AE 0.6</cell></row><row><cell>Median (range)</cell><cell>2.2 (1.0-3.0)</cell><cell>2.3 (1.1-2.8)</cell><cell>2.3 (1.0-3.0)</cell></row><row><cell>n</cell><cell>2 4</cell><cell>1 2</cell><cell>3 6</cell></row><row><cell>3-18 yrs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>9.3 AE 4.6</cell><cell>9.3 AE 3.4</cell><cell>9.3 AE 4.2</cell></row><row><cell>Median (range)</cell><cell>8.9 (3.0-17.2)</cell><cell>8.6 (4.2-15.8)</cell><cell>8.6 (3.0-17.2)</cell></row><row><cell>n</cell><cell>4 0</cell><cell>2 3</cell><cell>6 3</cell></row><row><cell>Male</cell><cell>39 (53)</cell><cell>25 (60)</cell><cell>64 (55)</cell></row><row><cell>Caucasian</cell><cell>66 (89)</cell><cell>36 (86)</cell><cell>102 (88)</cell></row><row><cell>Heart rate, beats/min</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>102 AE 21</cell><cell>100 AE 19</cell><cell>101 AE 20</cell></row><row><cell>Median (range)</cell><cell>101 (70-165)</cell><cell>96 (73-136)</cell><cell>100 (70-165)</cell></row><row><cell>Disease characteristics</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Time since diagnosis, months</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>47.6 AE 51.2</cell><cell>48.7 AE 47.7</cell><cell>48.0 AE 49.7</cell></row><row><cell>Median (range)</cell><cell>27.5 (1-200)</cell><cell>24.0 (1-169)</cell><cell>25.5 (1-200)</cell></row><row><cell>NHYA or Ross functional class</cell><cell></cell><cell></cell><cell></cell></row><row><cell>II</cell><cell>59 (80)</cell><cell>34 (81)</cell><cell>93 (80)</cell></row><row><cell>III</cell><cell>12 (16)</cell><cell>6 (14)</cell><cell>18 (16)</cell></row><row><cell>IV</cell><cell>3 (4)</cell><cell>2 (5)</cell><cell>5 (4)</cell></row><row><cell>LVEF, %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean AE SD</cell><cell>32 AE 8</cell><cell>3 5 AE 8</cell><cell>3 3 AE 8</cell></row><row><cell>Median (range)</cell><cell>32 (13-45)</cell><cell>37 (18-44)</cell><cell>34 (13-45)</cell></row><row><cell>NT-proBNP, pg/ml</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Geometric mean</cell><cell>478</cell><cell>495</cell><cell>484</cell></row><row><cell>Median (range)</cell><cell>376 (17-13,255)</cell><cell>393 (19-2,0227)</cell><cell>380 (17-20,227)</cell></row><row><cell>n</cell><cell>71</cell><cell>41</cell><cell>112</cell></row><row><cell>Dilated cardiomyopathy cause</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Idiopathic</cell><cell>45 (61)</cell><cell>20 (48)</cell><cell>65 (56)</cell></row><row><cell>Post-viral myocarditis</cell><cell>16 (22)</cell><cell>9 (21)</cell><cell>25 (22)</cell></row><row><cell>LV noncompaction</cell><cell>11 (15)</cell><cell>11 (26)</cell><cell>22 (19)</cell></row><row><cell>Ischemic</cell><cell>0</cell><cell>2 (5)</cell><cell>2 (2)</cell></row><row><cell>Post-anthracycline</cell><cell>2 (3)</cell><cell>0</cell><cell>2 (2)</cell></row><row><cell>Concomitant treatment</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACE inhibitors</cell><cell>70 (95)</cell><cell>39 (93)</cell><cell>109 (94)</cell></row><row><cell>Diuretic agents</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Aldosterone antagonists</cell><cell>63 (85)</cell><cell>28 (67)</cell><cell>91 (79)</cell></row><row><cell>Other diuretic agents</cell><cell>49 (66)</cell><cell>31 (74)</cell><cell>80 (69)</cell></row><row><cell>Beta-blocking agents</cell><cell>59 (80)</cell><cell>29 (69)</cell><cell>88 (76)</cell></row><row><cell>Digitalis</cell><cell>39 (53)</cell><cell>19 (45)</cell><cell>58 (50)</cell></row><row><cell>Angiotensin II antagonists</cell><cell>2 (3)</cell><cell>2 (5)</cell><cell>4 (4)</cell></row></table><note><p><s>(i.e., all patients having completed the titration period in accordance with the protocol).For the primary endpoint, treatment effect was estimated using a logistic regression model adjustedfor age group in the overall population, and unadjusted in each age class.</s><s>An estimate of the odds ratio (OR) between treatment groups and corresponding 95% confidence interval (CI) and p value are provided.</s><s>sponding CI and p values are provided.</s><s>For analysis of NYHA functional class or Ross class, we performed descriptive statistics on the changes from baseline at 6 and 12 months, expressed in terms of improvement, stability, or worsening in HF class.</s><s>A chi-square test was used to compare the percentage of patients who had an improvement in NYHA functional class or Ross class between treatment groups.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 2</head><label>2</label><figDesc><div><p><s>Primary Endpoint and Additional Parameter Changes in Full Analysis Set</s></p></div></figDesc><table><row><cell>Primary Endpoint at</cell><cell>Ivabradine</cell><cell>Placebo</cell><cell></cell><cell></cell></row><row><cell>End of Titration</cell><cell>(n ¼ 73)</cell><cell>(n ¼ 41)</cell><cell>Odds Ratio (95% CI)</cell><cell>p Value*</cell></row><row><cell>All children</cell><cell>51/73 (70)</cell><cell>5/41 (12)</cell><cell>17.24 (5.91 to 50.30)</cell><cell>&lt;0.0001</cell></row><row><cell>6-12 months</cell><cell>6/10 (60)</cell><cell>1/6 (17)</cell><cell>7.50 (0.62 to 90.63)</cell><cell>0.113</cell></row><row><cell>1-3 yrs</cell><cell>17/24 (71)</cell><cell>0/12 (0)</cell><cell>NA †</cell><cell></cell></row><row><cell>3-18 yrs</cell><cell>28/39 (72)</cell><cell>4/23 (17)</cell><cell>12.09 (3.35 to 43.66)</cell><cell>0.0001</cell></row><row><cell>Change in Heart Rate From Baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(beats/min)</cell><cell></cell><cell></cell><cell>Mean Difference (95% CI)</cell><cell></cell></row><row><cell>To end of titration</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>À21.2 AE 13.3</cell><cell>À1.4 AE 11.5</cell><cell>À18.99 (À23.75 to À14.23)</cell><cell>&lt;0.0001</cell></row><row><cell>6-12 months</cell><cell>À25.0 AE 12.4</cell><cell>À4.2 AE 16.5</cell><cell>À17.12 (À29.57 to À4.68)</cell><cell>0.0108</cell></row><row><cell>&gt;1 yr and &lt;3 yrs</cell><cell>À26.4 AE 11.2</cell><cell>1.3 AE 10.5</cell><cell>À27.54 (À35.59 to À19.50)</cell><cell>&lt;0.0001</cell></row><row><cell>3-18 yrs</cell><cell>À17.1 AE 13.6</cell><cell>À2.1 AE 10.9</cell><cell>À14.56 (À21.20 to À7.92)</cell><cell>&lt;0.0001</cell></row><row><cell>To 12 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>À20.8 AE 15.9</cell><cell>À3.0 AE 11.6</cell><cell>À16.63 (À21.91 to À11.34)</cell><cell>&lt;0.0001</cell></row><row><cell>Change in LVEF from Baseline, %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>To 6 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>11.4 AE 11.6 (n ¼ 72)</cell><cell>5.3 AE 10.3 (n ¼ 39)</cell><cell>5.11 (0.87 to 9.35)</cell><cell>0.0186</cell></row><row><cell>To 12 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>13.5 AE 13.1 (n ¼ 72)</cell><cell>6.9 AE 11.4 (n ¼ 39)</cell><cell>5.57 (0.75 to 10.40)</cell><cell>0.024</cell></row><row><cell>Change in Total PedQL ‡ Score From</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>To 6 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>9.1 AE 17.3 (n ¼ 36)</cell><cell>À1.5 AE 13.6 (n ¼ 19)</cell><cell>9.64 (1.83 to 17.46)</cell><cell>0.0166</cell></row><row><cell>To 12 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>9.1 AE 14.2 (n ¼ 36)</cell><cell>1.3 AE 15.3 (n ¼ 19)</cell><cell>6.92 (À0.08 to 13.93)</cell><cell>0.0527</cell></row><row><cell>Patients With Change in PedQL ‡ Score</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;4.5 From Baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>To 6 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>20/34 (59) (n ¼ 36)</cell><cell>9/19 (47) (n ¼ 19)</cell><cell></cell><cell>0.566</cell></row><row><cell>To 12 months</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All children</cell><cell>20/33 (61) (n ¼ 36)</cell><cell>10/19 (53) (n ¼ 19)</cell><cell></cell><cell>0.771</cell></row></table><note><p><s>Values are n/N (%) or mean AE SD unless otherwise indicated.*pvalue of test for heterogeneity of odds ratio (treatment Â age class) is 0.95 (NS).†Notapplicable;oddsratio could not be calculated because no patient in placebo group reached the primary endpoint.‡PedQLassessedbyparents.CI ¼ confidence interval; PedQL ¼ Pediatric Quality of Life inventory; other abbreviations as in Table1.RESULTSBASELINE CHARACTERISTICS.We enrolled 116 patients (n ¼ 74 ivabradine; n ¼ 42 placebo) with 17 children ages 6 to 12 months, 36 children ages &gt;1 year and &lt;3 years, and 63 children ages 3 to 18 years (Figure1).More than three-quarters of the patients (77%) completed the study and 23 (20%) withdrew due to AEs.At inclusion (Table1), the mean age was 5.8 AE4.9 years.</s><s>The majority (88%) of patients were Caucasian, and 55% were males.</s><s>The mean resting heart rate in the whole population was 101 AE 20 beats/ min; it was 131 AE 16 beats/min for children ages 6 to 12 months, 111 AE 11 beats/min for children ages &gt;1 year and &lt;3 years, and 87 AE 11 beats/min for children ages 3 to 18 years.</s><s>HEART RATE REDUCTION AND DOSE.</s><s>For all age groups combined, the primary endpoint ($20% reduction of the baseline resting heart rate without bradycardia or symptoms of bradycardia) was reached by more children receiving ivabradine (70%) than placebo (12%) in the FAS population.</s><s>The betweengroup comparison was statistically significant in</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 3</head><label>3</label><figDesc><div><p><s>Ivabradine Dosing: Per-Protocol Population* of Children Who Reached the Primary Endpoint The mean doses of ivabradine during titration and the dose at the end of titration are described in Table3for children in the per-protocol population</s></p></div></figDesc><table><row><cell>J A C C V O L . 7 0 , N O . 1 0 , 2 0 1 7</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bonnet et al.</cell></row><row><cell>S E P T E M B E R 5 , 2 0 1 7 : 1 2 6 2 -7 2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Ivabradine in Pediatric Heart Failure</cell></row><row><cell></cell><cell></cell><cell cols="3">FIGURE 2 Heart Rate at Rest</cell><cell></cell><cell></cell></row><row><cell>Age 6-12 months</cell><cell></cell><cell></cell><cell>120</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean dose during titration period, mg/kg</cell><cell>0.09 AE 0.04 (0.11)</cell><cell></cell><cell>110</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose at the end of titration period, mg/kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.02 0.05 0.10 0.15 0.20</cell><cell>1/4 (25) --1/4 (25) 2/4 (50)</cell><cell>Heart Rate (bpm)</cell><cell>100 90 80</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age &gt;1 yr and &lt;3 yrs</cell><cell></cell><cell></cell><cell>70</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean dose during titration period, mg/kg</cell><cell>0.13 AE 0.04 (0.15)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose at the end of titration period, mg/kg</cell><cell></cell><cell></cell><cell cols="2">Baseline 60</cell><cell>End of Titration</cell><cell>6 Months</cell><cell>12 Months</cell></row><row><cell>0.05</cell><cell>1/14 (7)</cell><cell cols="2">Ivabradine (n)</cell><cell>73</cell><cell>73</cell><cell>65</cell><cell>61</cell></row><row><cell>0.10</cell><cell>3/14 (21)</cell><cell>Placebo (n)</cell><cell></cell><cell>41</cell><cell>41</cell><cell>29</cell><cell>28</cell></row><row><cell>0.15</cell><cell>1/14 (7)</cell><cell></cell><cell></cell><cell></cell><cell>Ivabradine</cell><cell>Placebo</cell></row><row><cell>0.20</cell><cell>1/14 (7)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.30</cell><cell>8/14 (57)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age 3-18 yrs, &lt;40 kg Mean dose during titration period, mg/kg</cell><cell>0.10 AE 0.04 (0.11)</cell><cell cols="6">Mean resting heart rate began decreasing with ivabradine almost immediately upon administration.</cell></row><row><cell>Dose at the end of titration period, mg/kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.05</cell><cell>4/17 (24)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.10</cell><cell>3/17 (18)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.15</cell><cell>3/17 (18)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.20</cell><cell>5/17 (29)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.30</cell><cell>2/17 (12)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age 3-18 yrs, &gt;40 kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean dose during titration period, mg/kg</cell><cell>4.06 AE 2.16 (3.27)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose at the end of titration period, mg/kg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2.5</cell><cell>4/11 (36)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>5.0</cell><cell>5/11 (46)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>7.5</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell>-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>15</cell><cell>2/11 (18)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Values are mean AE SD (median) or n/N (%).*The mean dose was defined as the sum of doses prescribed, taking into account the number of days for which a dose was prescribed during the titration period.Dosing was twice daily.encedasymptomatic</s><s>bradycardia.Regardless of age, the effect of ivabradine upon resting heart rate was variable, with some patients reaching the primary endpoint at the lowest dose of ivabradine.Titration profiles varied markedly across patients.However, for most patients(32 [43%]in the ivabradine group), titration consisted of 4 steps of continuous dose increase.</s><s>SECONDARY OUTCOMES.</s><s>An improvement in NYHA functional class or Ross class from baseline was observed in 32% of patients taking ivabradine versus 17% of patients taking placebo by 6 months (p ¼ 0.132).</s><s>Similar results were observed by 12 months (38% vs. 25%; p ¼ 0.239) (Figure 3A).</s><s>Most patients retained a stable NYHA functional class or 12 months; E AE SE: À10.71 AE 4.26 ml; 95% CI: À19.15 to À2.26; p ¼ 0.013).</s><s>There was also a decrease in LV end-diastolic volume with ivabradine in comparison with baseline (À8.4 AE 34.1 ml), versus a slight increase with placebo (2.6 AE 26.3 ml); however, the mean difference between treatment was not significant (E AE SE: À7.91 AE 5.69 ml; 95% CI: À19.19 to 3.38; p ¼ 0.168).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc><div><p><s>The overall safety of ivabradine was comparable to the placebo group.</s><s>Adverse events were</s></p></div></figDesc><table><row><cell></cell><cell>reported at a similar frequency in both treatment</cell></row><row><cell></cell><cell>groups (86% with ivabradine vs. 88% with placebo)</cell></row><row><cell></cell><cell>(Table 4). The most frequently affected system organ</cell></row><row><cell></cell><cell>classes were infections and infestations (mainly</cell></row><row><cell></cell><cell>nasopharyngitis, bronchitis, upper respiratory tract</cell></row><row><cell></cell><cell>infection, and viral infection), and gastrointestinal</cell></row><row><cell></cell><cell>disorders (mainly gastroenteritis, diarrhea, and</cell></row><row><cell></cell><cell>vomiting), with a lower frequency of AEs with ivab-</cell></row><row><cell></cell><cell>radine than placebo. A prolonged QTc interval was</cell></row><row><cell></cell><cell>observed less frequently with ivabradine than pla-</cell></row><row><cell></cell><cell>cebo (8% vs. 17%), and led to study withdrawal in 4%</cell></row><row><cell></cell><cell>and 7% of patients, respectively. None of the emer-</cell></row><row><cell></cell><cell>gent QTc prolongations in the ivabradine group were</cell></row><row><cell></cell><cell>serious or symptomatic. Phosphenes were reported at</cell></row><row><cell></cell><cell>a similar frequency in both groups. None of the pa-</cell></row><row><cell></cell><cell>tients reported blurred vision. Globally, cardiac con-</cell></row><row><cell></cell><cell>cerns were reported less frequently by patients on</cell></row><row><cell></cell><cell>ivabradine than placebo (15% vs. 31%, respectively),</cell></row><row><cell></cell><cell>and led to withdrawal in the placebo group only.</cell></row><row><cell></cell><cell>Bradycardia-asymptomatic cases included-was re-</cell></row><row><cell></cell><cell>ported with a higher frequency with ivabradine than</cell></row><row><cell></cell><cell>placebo (11.0% vs. 2.4%). Symptomatic bradycardia</cell></row><row><cell></cell><cell>was reported in the ivabradine group only: 4% in the</cell></row><row><cell></cell><cell>age &gt;1 year and &lt;3 years subgroup and 5% in the age</cell></row><row><cell></cell><cell>3 to 18 years subgroup. Emergent bradycardia led to a</cell></row><row><cell></cell><cell>dose reduction in 6 patients (1.6%), all with ivabra-</cell></row><row><cell></cell><cell>dine, none of which led to study withdrawal. No</cell></row><row><cell></cell><cell>patient died in the ivabradine group, but 4 patients</cell></row><row><cell></cell><cell>(9.5%) died in the placebo group (between-group</cell></row><row><cell></cell><cell>difference: p ¼ 0.016) (Table 4). A total of 3 heart</cell></row><row><cell></cell><cell>transplants were performed (2.5%): 1 in the ivabra-</cell></row><row><cell></cell><cell>dine group and 2 in the placebo group. Additionally, 1</cell></row><row><cell></cell><cell>patient on ivabradine underwent a heart transplant</cell></row><row><cell>QUALITY OF LIFE. A total of 69 patients were</cell><cell>2 months after the last study drug intake.</cell></row><row><cell>included in the QOL substudy (n ¼ 44 ivabradine;</cell><cell></cell></row><row><cell>n ¼ 25 placebo). QOL was evaluated by the parents</cell><cell>DISCUSSION</cell></row><row><cell>(n ¼ 36 ivabradine; n ¼ 19 placebo) and/or by the</cell><cell></cell></row><row><cell>children themselves (n ¼ 17 ivabradine; n ¼ 11 pla-</cell><cell>In children with DCM and symptomatic chronic HF,</cell></row><row><cell>cebo). At baseline, the total score was similar in both</cell><cell>adding ivabradine to stable HF therapy (including</cell></row><row><cell>treatment groups (parent-reported: 67.4 AE 19.2 with</cell><cell>beta-blockers) could reduce heart rate by more than</cell></row><row><cell>ivabradine vs. 69.6 AE 14.8 with placebo; child-</cell><cell>20% in a clear majority of children without inducing</cell></row><row><cell>reported: 71.3 AE 14.1 vs. 70.0 AE 9.9, respectively). The</cell><cell>bradycardia. Ivabradine showed similar efficacy for</cell></row><row><cell>parent questionnaires showed an improvement in to-</cell><cell>reducing heart rate in a wide range of age classes, from</cell></row><row><cell>tal score in favor of ivabradine at 6 months and a trend</cell><cell>6 months to 18 years (Central Illustration). We</cell></row><row><cell></cell><cell>observed a high interindividual variability in response</cell></row><row><cell></cell><cell>to ivabradine, indicating that dose titration is</cell></row><row><cell></cell><cell>important-and should be mandatory-when used to</cell></row><row><cell></cell><cell>treat children with chronic HF. Ivabradine treatment</cell></row><row><cell></cell><cell>was associated with significant improvement in LVEF</cell></row><row><cell></cell><cell>(þ14%) and LVESV (À16.2 AE 27.0 ml) at 12 months,</cell></row></table><note><p><s>in improvement at 12 months (Table2).The children's questionnaires did not show any relevant change during the study or any between-group difference (p ¼ 0.71 at 12 months).By 6 months, the assessments reported by the parents showed an improvement of &gt;4.5 in the PedQL total scale score in 59% of children on ivabradine and in 47% of children on placebo (Table2); similar results were observed at 12 months.SAFETY.greater</s><s>than that seen with placebo (þ7% and À1.9 ml for LVEF and LVESV, respectively).</s><s>In line with this</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE 4</head><label>4</label><figDesc><div><p><s>Values are n (%).</s><s>*Includes asymptomatic bradycardia, with symptomatic bradycardia reported only in the ivabradine group.</s><s>Emergent bradycardia did not lead to withdrawal, but did lead to a dose reduction in 6 patients (1.6%).</s><s>†None of the emergent QTc prolongations were either serious or symptomatic in the ivabradine group.</s><s>‡1 septic shock, 1 sudden cardiac arrest, 1 ventricular tachycardia, and 1 ventricular fibrillation.</s><s>§1 atrial flutter, 1 worsening of chronic heart failure, 1 cardiogenic shock, and 1 low cardiac output syndrome.</s><s>ǁp value not calculated in view of the small number of patients.</s></p></div></figDesc><table><row><cell>Adverse Events</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Difference</cell></row><row><cell></cell><cell>Ivabradine</cell><cell>Placebo</cell><cell>Between Group</cell></row><row><cell></cell><cell>(n ¼ 73)</cell><cell>(n ¼ 42)</cell><cell>p Value</cell></row><row><cell>TEAE</cell><cell></cell><cell></cell><cell></cell></row><row><cell>All</cell><cell cols="2">63 (86.3) 37 (88.1)</cell><cell>1.000</cell></row><row><cell cols="3">Infections and infestations 50 (68.5) 31 (73.8)</cell><cell>0.672</cell></row><row><cell>Investigations</cell><cell cols="2">21 (28.8) 16 (38.1)</cell><cell>0.310</cell></row><row><cell>Gastrointestinal</cell><cell cols="2">21 (28.8) 15 (35.7)</cell><cell>0.532</cell></row><row><cell>Eye disorders</cell><cell>9 (12.3)</cell><cell>6 (14.3)</cell><cell>0.780</cell></row><row><cell>Phosphenes</cell><cell>2 (2.7)</cell><cell>1 (2.4)</cell><cell>1.000</cell></row><row><cell>Cardiac disorders</cell><cell>11 (15.1)</cell><cell>13 (31.0)</cell><cell>0.057</cell></row><row><cell>Bradycardia*</cell><cell>8 (11)</cell><cell>1 (2.4)</cell><cell>0.152</cell></row><row><cell>Prolonged QTc interval †</cell><cell>6 (8)</cell><cell>7 (17)</cell><cell>0.223</cell></row><row><cell>Deaths</cell><cell>0</cell><cell>4 (9.5) ‡</cell><cell>0.016</cell></row><row><cell>WEAE</cell><cell></cell><cell></cell><cell></cell></row><row><cell>All</cell><cell>4 (5.5)</cell><cell>8 (19.1)</cell><cell>0.029</cell></row><row><cell>Prolonged QTc interval</cell><cell>3 (4.1)</cell><cell>3 (7.1)</cell><cell>0.667</cell></row><row><cell>Cardiac disorders</cell><cell>0</cell><cell>4 (9.5) §</cell><cell>0.016</cell></row><row><cell>Gastrointestinal disorders</cell><cell>0</cell><cell>1 (2.4)</cell><cell>NCǁ</cell></row><row><cell>Heart transplant</cell><cell>1 (1.4)</cell><cell>2 (4.8)</cell><cell>0.25</cell></row></table><note><p><s>NC ¼ not calculated; TEAE ¼ treatment-emergent adverse events; WEAE ¼ emergent adverse events leading to treatment withdrawal.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JACC VOL. 70, NO. 10, 2017 Ivabradine in Pediatric Heart Failure S E P T E M B E R 5 , 2 0 1 7 : 1 2 6 2 -7 2</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J A C C V O L . 7 0 , N O . 1 0 , 2 0 1 7Bonnet et al.S E P T E M B E R 5 , 2 0 1 7 : 1 2 6 2 -7 2Ivabradine in Pediatric Heart Failure</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Ivabradine in Pediatric Heart Failure</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Pediatric versus adult cardiomyopathy and heart failure-related hospitalizations: a value-based analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Wittlieb-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Zaoutis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="76" to="82" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The incidence of pediatric cardiomyopathy in two regions of the United States</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lipshultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sleeper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Towbin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope unit="page" from="1647" to="1655" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The epidemiology of childhood cardiomyopathy in Australia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Nugent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Daubeney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chondros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope unit="page" from="1639" to="1646" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Incidence, causes, and outcomes of dilated cardiomyopathy in children</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Towbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Colan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="1867" to="1876" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Recovery of echocardiographic function in children with idiopathic dilated cardiomyopathy: results from the pediatric cardiomyopathy registry</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Everitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sleeper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1405" to="1413" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Daubeney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Nugent</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy</title>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="2039" to="2046" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lipshultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Cochran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Briston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future Cardiol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="817" to="848" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Kantor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lougheed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dancea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Cardiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1535" to="1552" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Dipchand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Rosenthal</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>cor-</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Heart Lung Transplant</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="888" to="909" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Congestive heart failure in pediatric patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Colan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Graham</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="923" to="928" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Management of chronic congestive heart failure in children</title>
		<author>
			<persName><forename type="first">I</forename><surname>Balfour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Treat Options Cardiovasc Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="407" to="416" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Carvedilol for children and adolescents with heart failure: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Shaddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Boucek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page" from="1171" to="1179" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Predictors of mortality and morbidity in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pfeffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="65" to="75" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The myocardium in congestive heart failure</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="12A" to="16A" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers</title>
		<author>
			<persName><forename type="first">G</forename><surname>Flannery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gehrig-Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Billah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Krum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="865" to="869" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Komajda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="875" to="885" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">for the ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adamopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1787" to="1847" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Grading the severity of congestive heart failure in infants</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Bollinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Pinsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Cardiol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="72" to="75" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment</title>
		<author>
			<persName><forename type="first">S</forename><surname>Peigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bouzom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Brendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fouliard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chenel</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Pharmacokinet Pharmacodyn</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="13" to="27" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment</title>
		<author>
			<persName><forename type="first">S</forename><surname>Peigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fouliard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Decourcelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chenel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacokinet Pharmacodyn</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="29" to="43" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">New normal limits for the paediatric electrocardiogram</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Rijnbeek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Witsenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schrama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Kors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="702" to="711" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">New inotropic pharmacologic strategies targeting the failing myocardium in the newborn and infant</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Delgizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Veldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schranz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AACN Clin Issues Crit Care Nurs</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="785" to="792" />
			<date type="published" when="1990">1990. 2006</date>
		</imprint>
	</monogr>
	<note>Mini Rev Med Chem</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bohm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Komajda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="886" to="894" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Varni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Kurtin</surname></persName>
		</author>
		<ptr target="https://www.meddra.org/" />
	</analytic>
	<monogr>
		<title level="j">Med Care</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="800" to="812" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>The Medical Dictionary for Regulatory Activities</note>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Accessed</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2017-07-20">July 20, 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Beta-blockers for congestive heart failure in children</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Frobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hulpke-Wette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="page">D007037</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Beta-adrenergic receptor antagonists and chronic heart failure in children</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Filippo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ther Clin Risk Manag</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="847" to="854" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Parsons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="847" to="849" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rosenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Chrisant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Edens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Heart Lung Transplant</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1313" to="1333" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Update on pharmacological heart failure therapies in children: do adult medications work in children and if not, why not?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Rossano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Shaddy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="607" to="612" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a</title>
		<author>
			<persName><forename type="first">M</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
